Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2002

View Archived Issues

Elan repositions business for long-term growth

Genta evaluates Genasense in children with solid tumors

Paladin seeks marketing approval for Statex SR in Canada

Pfizer's pregabalin regulatory submission delayed

AMD-3100 enters phase I trial in cancer patients for stem cell transplantation

Phase II FluINsure trial completes enrollment

First filing made for new anticoagulant Exanta

Weight loss induced by Axokine is maintained for a year after end of treatment

Combining A-200, ephedrine and caffeine does not enhance weight loss in obese patients

Bupropion reported to enhance weight loss in dieting patients with depressive symptoms

Weight-lowering effects of anticonvulsants

New data support single daily doses of LY-307161 SR to treat type 2 diabetes

Clinical pharmacokinetic and safety data reported for insulin detemir

Orally active B-cell IgE synthesis inhibitors discovered by Novartis team

Sigma-Tau synthesizes phenylalkylcarboxylates with superior profile to rosiglitazone

CSP-2503: a potent and selective 5-HT1A agonist with anxiolytic activity

Syk inhibitors synthesized at Novartis as novel therapeutics for asthma

Potent and selective VR1 antagonist described in recent abstract

Potential new treatments for chronic bronchitis targeting 15-LO sought by Pfizer

Active metabolite of caspofungin prepared and tested at Merck

Prostaglandin analogues for restenosis following PTCA presented by Taisho

New MMP inhibitors for use in inflammatory disorders

Prodrugs of kainate receptor modulators with potential in pain and cognition disorders

New PDE4 inhibitors prepared and tested at Mercian

PI-88 enters phase I in combination with Taxotere

Suntory and Daiichi to establish new pharma company

FDA advisory committee recommends approval of Spiriva